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Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained
From New York State
Abstract
International guidelines recommend using local susceptibility data to direct empiric therapy for acute
uncomplicated cystitis. We evaluated outpatient urinary isolate susceptibility trends in New York State.
Nitrofurantoin had the lowest resistance prevalence whereas trimethoprim-sulfamethoxazole and
fluoroquinolones had higher prevalences. This study highlights the need for local outpatient antimicrobial
stewardship programs.

Disciplines
Pharmacy and Pharmaceutical Sciences

Comments
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution,
and reproduction in any medium, provided the original work is properly cited.
This article can also be found on the publisher's webpage: https://doi.org/10.1093/ofid/ofy297

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0
International License.

Authors
Elliot L. Rank, Thomas Lodise, Lisa M. Avery, Eve Bankert, Erica Dobson, Ghinwa Dumyati, Stephen
Hassett, Marina Keller, Matthew Pearsall, Theresa Lubowski, and Joseph J. Carreno

This article is available at Fisher Digital Publications: https://fisherpub.sjf.edu/pharmacy_facpub/176

Open Forum Infectious Diseases
BRIEF REPORT

Elliot L. Rank,1 Thomas Lodise,2 Lisa Avery,3 Eve Bankert,4
Erica Dobson,5 Ghinwa Dumyati,6 Stephen Hassett,7
Marina Keller,8 Matthew Pearsall,9 Teresa Lubowski,10 and Joseph J. Carreno2,
1

Microbiology, Quest Diagnostics, Teterboro, New Jersey; 2Pharmacy Practice, Albany College
of Pharmacy and Health Sciences, Albany, New York; 3Pharmacy Practice, Wegmans School
of Pharmacy/St. John Fisher College, Rochester, New York; 4Island Peer Review Organization,
Albany, New York; 5Pharmacy, University of Rochester Medical Center, Rochester, New York;
6
Infectious Diseases Division, University of Rochester, Rochester, New York; 7Emergency
Medicine, Albany Med EmUrgent Care, Albany, New York; 8Infectious Disease, Orange
Regional Medical Center, Middletown, New York; 9Pharmacy, Glens Falls Hospital, Glens Falls,
New York; 10Island Peer Review Organization, Albany, New York

International guidelines recommend using local susceptibility
data to direct empiric therapy for acute uncomplicated cystitis.
We evaluated outpatient urinary isolate susceptibility trends
in New York State. Nitrofurantoin had the lowest resistance
prevalence whereas trimethoprim-sulfamethoxazole and fluoroquinolones had higher prevalences. This study highlights the
need for local outpatient antimicrobial stewardship programs.
Keywords. antibiogram; antimicrobial resistance; New
York State; urinary tract infection.

Acute uncomplicated cystitis is a prevalent outpatient condition
[1, 2]. It is estimated that there are approximately 6–8 million
annual visits to a physician or clinic by patients for treatment of
an acute uncomplicated cystitis event [3, 4]. Treatment guidelines for acute uncomplicated cystitis in premenopausal, nonpregnant women are well defined in international guidelines [2].
In these international guidelines, empiric treatment recommendations are provided, but these empiric recommendations
are accompanied by the caveat that empiric antibiotic selection
should be guided by local organism susceptibility data and
patient-specific risk factors.
Although treatment selection for acute uncomplicated cystitis was straightforward in the past, management of these conditions has been complicated by reports of rising antibiotic
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resistance rates for several key urinary pathogens. It is important to note that much of the data that describe rising rates of
resistance for uncomplicated cystitis pathogens were derived
from hospitalized inpatients with urinary tract infections. Data
that describe outpatient resistance rates are consistent with published inpatient reports but are limited [5]. It is also unclear if
resistance rates among acute uncomplicated cystitis pathogens
are applicable to all age groups, and to both men and women.
Given these gaps in the literature, this study sought to describe
the prevalence and resistance patterns of urinary pathogens in
New York State in the outpatient setting. The intent was to use
these data to help inform treatment decisions for patients who
present with uncomplicated cystitis in the outpatient setting
and to assess the appropriateness of empiric treatment recommendations found in national guidelines for New York State.
METHODS

A retrospective analysis was conducted on all urine cultures
received from outpatient settings (defined as physician offices
or outpatient clinics), with antimicrobial susceptibility testing performed from January 1, 2016, to December 31, 2016,
at a major clinical microbiology reference laboratory (Quest
Diagnostics Laboratory, Teterboro, NJ). As antimicrobial testing is not routinely recommended for Streptococcus agalactiae
and Staphylococcus saprophyticus, these organisms were not
included in the analysis. Data from 17 New York State counties
were included in the overall sample (Table 1). Urine cultures
demonstrating 1 or 2 bacterial isolates at >105 colony-forming
units/mL were included (only the first reported isolate from
dual infections was included). In accordance with standards for
summarizing antimicrobial susceptibilities for antibiograms,
each species required a minimum of 30 isolates for inclusion in
antimicrobial susceptibility estimates.
Urine pathogens were isolated from bi-plates of Trypticase
Soy Agar with 5% Sheep Blood (TSA II) and MacConkey II
Agar, followed by identification and automated drug susceptibility testing (Vitek-2). Antimicrobials tested included ampicillin,
ceftazidime, cefazolin, ciprofloxacin, nitrofurantoin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, tetracycline,
oxacillin, and vancomycin, as appropriate. Minimum inhibitory
concentration (MIC) susceptibility interpretations were derived
from CLSI M100 S-25 [6]. Antibiotic sensitivity percentages are
reported as number of susceptible isolates divided by number
of isolates tested. Susceptibility was reported overall and by
sex and age (children: ≤17 years; adults: 18–64 years; and older
adults: ≥65 years). Chi-square tests or Fisher exact tests were
used to compare the overall prevalence of bacterial resistance
BRIEF REPORT • OFID • 1
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Pseudomonas aeruginosa (15), Serratia marcescens (9), Staphylococcus haemolyticus (9), Staphylococcus hominis spp. hominis (3), Staphylococcus ludgunensis (0), Staphylococcus simulans (24), Stenotrophomonas maltophila (1), vancomycin-resistant
Enterococcus faecium (0).
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faecium (11).

e

d

Females <18 years: Citrobacter diversus (29 isolates), Citrobacter freundii (11), Enterobacter aerogenes (19), Enterobacter cloacae (27), methicillin-resistant S. aureus (5), Providencia rettgeri (1), Serratia marcescens (7), Staphylococcus haemolyticus (9),
Staphylococcus hominis spp. hominis (4), Staphylococcus ludgunensis (1), Staphylococcus simulans (25), Stenotrophomonas maltophila (2), vancomycin-resistant Enterococcus faecium (0).

c

Organisms not reported due to <30 isolates in the reporting group:

Data not shown for 1739 coagulase-negative staphylococci.

N = total number of antimicrobial testing results.

b

a

Abbreviations: Pip-Tazo, piperacillin-tazobactam; TMP-SMX, trimethoprim/sulfamethoxazole.
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within and between agents tested and between age and sex
groups.
RESULTS

DISCUSSION

The current Infectious Disease Society of America (IDSA)
guidelines for acute uncomplicated cystitis recommend nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin as
firstline agents for treatment [2]. Overall, we found that bacterial isolates in the outpatient setting in New York State were 90%
sensitive in vitro to nitrofurantoin. The high probability of in
vitro activity with nitrofurantoin is likely due to the high prevalence and susceptibility rates for E. coli. Although the IDSA
guidelines do not define a resistance prevalence threshold for
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A total of 78 078 urine culture susceptibility reports were
included (Table 1). The majority of the urine cultures were
obtained from female patients. The most frequently recovered
isolates were Escherichia coli, 65.1%; Enterococcus spp., 11.9%;
and Klebsiella pneumoniae, 10.0%. Among isolates recovered
from females, the distribution was consistent with the overall
study population. In men, the prevalence of E. coli was lower
(40.3 %) relative to the overall population, whereas the prevalence of Enterococcus was higher (22.1%). In children, E. coli
was the most prevalent isolate (73.7%), followed by Enterococcus
(10.4%) and Proteus species (6.8%). The distribution of pathogens in adult (age 18–64 years) patients was similar to the
overall population: E. coli (68.5%), Enterococcus (11.2%), and
K. pneumoniae (8.7%). In older adults, the prevalence of E. coli
was lower (58.7%), whereas the prevalence rates of Enterococcus
and Klebsiella were higher (12.2% and 12.8%, respectively).
Of all the isolates tested for nitrofurantoin sensitivity
(n = 73 191), 90.4% were susceptible. Nitrofurantoin resistance
was more commonly noted in males as compared with females
(10.6% vs 9.1%, P < .001) and older adults as compared with all
other ages combined (12.3% vs 8.1%, P < .001). High overall
rates of susceptibility were reported for isolates tested for cefazolin sensitivity (90.4%). However, due to the high prevalence of
Enterococcus spp. (which is intrinsically resistant to cefazolin),
cefazolin only has activity against 68.2% of the isolates. Only
77.2% of all isolates tested (n = 67 711) were trimethoprim-sulfamethoxazole susceptible. Resistance to trimethoprim-sulfamethoxazole was more prevalent in men than women (26.3%
vs 22.7%, P < .001) and in older adults than all other age groups
combined (25.1% vs 22.1%, P < .001). Of the isolates tested for
ciprofloxacin sensitivity (n = 68 709), 80.2% were susceptible.
Resistance to ciprofloxacin was more frequent in males than
females (35.0% vs 17.3%, P < .001) and in older adults than in
all other ages combined (30. % vs 14.0%, P < .001). Additional
data on pathogen-specific sensitivity overall and by sex and age
groups are presented in Table 1. County-specific data are provided in the Supplementary Data.

assessing the appropriateness of nitrofurantoin for empiric use
in treating acute uncomplicated cystitis, if we apply the trimethoprim-sulfamethoxazole threshold (20%, per the IDSA
guidelines), our data support the utilization of nitrofurantoin
in the New York State outpatient setting for this condition.
In contrast, trimethoprim-sulfamethoxazole appears to have
more limited utility as an empiric treatment regimen for acute
uncomplicated cystitis as the overall prevalence of trimethoprim-sulfamethoxazole resistance exceeded 20%. Unfortunately,
fosfomycin susceptibility data were unavailable in this data set
as testing was not routinely performed. Given the limited activity of trimethoprim-sulfamethoxazole and ciprofloxacin for
acute uncomplicated cystitis, it would be prudent for laboratories to consider testing of fosfomycin in urinary isolates, especially for Escherichia coli and Enterococcus faecalis. In species
other than Escherichia coli and Enteroccocus faecalis, the utility
and validity of susceptibility results for fosfomycin have yet to
be determined [6]. Importantly, recent data show that 1 day
of fosfomycin is inferior to 5 days of nitrofurantoin for acute
uncomplicated cystitis [7]. As such, fosfomycin should be used
with caution when treating acute uncomplicated cystitis.
Susceptibility results from this study were also unfavorable to
the empiric use of fluoroquinolones and β-lactam antibiotics.
The overall prevalence of ciprofloxacin resistance was 19.8%,
exceeding the IDSA-recommended 10% resistance threshold
for empiric use. In light of the relatively high prevalence of fluoroquinolone resistance as well as growing concerns about fluoroquinolone-associated disability, our study supports the recent
Food and Drug Administration recommendation to avoid
empiric fluoroquinolone use unless no other alternative agents
are available [7]. We also examined cefazolin as a surrogate for
cephalexin susceptibility. When only Gram-negative bacterial
species were isolated, cefazolin appeared to be an appropriate
empiric agent. However, the utility of cefazolin as an empiric
agent is less than favorable due to the high prevalence of
Enterococcus, an organism that is intrinsically resistant to cefazolin. Given that β-lactam medications require longer duration
of treatment as compared with other therapies and are associated with lower efficacy [8], our data suggest that β-lactam
drugs should be considered as empiric agents only when potential benefits outweigh risks.
These data also indicate that the overall antimicrobial susceptibility percentages of antimicrobials are significantly lower for
individuals in the ≥65 age group compared with all other ages
combined and among males of all ages compared with females.
These findings highlight the need to not rely exclusively on
overall susceptibility results and to consider sex, age, and prior
urine culture results when selecting an agent for a given patient.
As susceptibility rates varied by age and sex, subsequent adjustment of therapy based on individualized culture and susceptibility reports should be performed in an effort to promote use
of narrow-spectrum antibiotics where possible.
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Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
the authors, so questions or comments should be addressed to the corresponding author.
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There are several caveats to be considered with respect to
these findings. We did not include coagulase-negative staphylococci in this analysis due to its questionable pathogenicity.
However, our conclusions would be affected minimally by the
inclusion of coagulase-negative staphylococci because coagulase-negative staphylococci only accounted for 2% of isolates.
Another potential limitation of this study is lack of data on
clinical presentation of the patients. We did not determine
whether these were symptomatic urinary tract infections or
asymptomatic bacteriuria. Last, this study may overrepresent
antimicrobial resistance rates as practitioners may only send
urine cultures for patients with recurrent infections or treatment failure.
Although these data are from New York State, there are
several generalizable aspects of this study. First, this project
highlights the framework for creating a regional antibiogram.
Regional antibiograms are important tools that could be used
by health departments and other regional authorities to help
influence prescribing and/or track antimicrobial resistance
for key pathogens. Second, New York State (especially Kings,
Queens, New York, Bronx, and Richmond counties, the 5 New
York City counties) is unique in that it has an incredibly high
population density [9]. Along with antimicrobial utilization,
population density has been shown to be associated with antimicrobial resistance prevalence [10]. Hence, it stands to reason
that New York State can be thought of as a regional bellwether
for antimicrobial resistance.
In summary, we conducted a 1-year retrospective analysis
of outpatient urine isolates collected from patients in New
York State. Data indicated that nitrofurantoin has retained
activity against many of the urinary pathogens since the publication of the 2011 IDSA guidelines and has a high prevalence of in vitro activity. In contrast, we found that the overall
prevalence of resistance in bacterial urinary isolates exceeded
the predefined IDSA empiric therapy thresholds of 20% for
trimethoprim-sulfamethoxazole and 10% for fluoroquinolones, with resistance rates being highest in patients ≥65 years.
These data highlight the need in outpatient settings for (1)
urinary culture specimen submission, (2) antimicrobial stewardship efforts, and (3) assembly of local susceptibility data
to guide empiric therapy in acute uncomplicated cystitis.
Finally, these data also support the desperate need for new
oral antimicrobials to treat acute uncomplicated cystitis in
the outpatient setting.

